

MITreg Checklist

1) Cells at the start of procedure

a) Essential information about the donor

i) Species and strain

Species

Strain (if applicable)

ii) Characteristics of the organism

Health

Age

Treatment/Environment

Individual identifier number

Source of purchase (if applicable)

b) Source of cell material

Organ, tissue, fluid or blood product

Source (if applicable)

Quantity (volume, size or weight)

Anti-coagulant (if applicable)

If using cryopreserved sample:

Method and duration of storage

Initial cell counts

Ethical committee approval/ written informed consent

c) Cell separation process

i) Cell handling and labelling

Cell extraction method

Tissue conditions between tissue retrieval and cell separation

Duration

Temperature

Container

Fluid

Cell labelling

Buffers and reagents (incl. source)

Cell suspension volume and concentration

Incubation temperature and duration

Washing steps

ii) Cell separation equipment and process

Methodology

Equipment

Presence of target cells in starting material described

d) Phenotype

For any of the below, indicate the percentage of cells displaying the characteristic (if known)

i) Cell surface and intracellular markers

Molecules measured (using CD names)

Details of reagents used and source (incl. mAb clone, fluorochrome)

Methodology

Stimulus and time of stimulation (if applicable)

Gating strategy to determine positive cells

ii) Secreted molecules

Molecules measured

Details of reagents used (incl. mAb clone, conjugate) and source

Methodology

Cell density/ml of medium and type of tissue culture plate

Time point of supernatant collection

Stimulus and time of stimulation (if applicable)

iii) Epigenetic modifications

Epigenetic modification relevant to the characteristics

iv) Specificity

Specificity of the cells (polyclonal or antigen-specific)

Methodology used to obtain specificity

Methodology used to confirm specificity

e) Cell numbers**i) Absolute cell number**

Total number of cells at the end of the isolation process

Methodology

ii) Viability

Percentage of viable cells

Methodology

2. Expansion/Differentiation**a) Pre-culture conditions**

Storage conditions

Fluid

Type of container

Temperature

Fresh or thawed

Storage time

b) Culture conditions***i) Cell number***

The total number of cells put into culture

ii) Cell concentration

The number of cells per ml of medium at start of culture

iii) Culture medium

Type(s) of medium

Source(s)

Additives (excluding agents to maintain/induce Tregs)

Refreshment of the medium

iv) Culture container

Type of container

Size

Manufacturer

Cell culture volume per container or well

Total number of containers or wells

v) Culture environment

Temperature and CO₂ concentration

Use of pre-warmed medium

Equipment

c) Differentiation/tolerization protocol

Name of cytokine(s) or other agent(s) used

Concentrations

Time-point(s) added to cell culture

Total length of the culture period

Rounds of stimulation

Number of cell splitting

d) Stimulus

Polyclonal/antigen-specific/allo-antigen

Stimulus (agent and/or accessory cell)

Source

Concentration

Time point(s) added to culture

Restimulation conditions (if applicable)

e) Storage

Storage time

Storage conditions

If fresh

Fluid

Container

Temperature

If cryopreserved

Freezing/thawing process
 Freezing medium
 Cell recovery & viability after thawing
 Time point at which cells are stored if different
 to the end of the culture process

3. Cells after expansion/differentiation

a) Phenotype

For any of the below, indicate the percentage of cells displaying the characteristic (if known)
 Stability of the phenotype (if tested)
 Phenotype tested on fresh or thawed cells

i) Cell surface and intracellular markers

Molecules measured (using CD names)
 Details of reagents used and source
 Methodology
 Stimulus and time of stimulation (if applicable)
 Gating strategy to determine positive cells

ii) Secreted molecules

Molecules measured
 Details of reagents used and source
 Methodology
 Cell density/ml of medium and type of tissue culture plate
 Time point of supernatant collection
 Stimulus and time of stimulation (if applicable)

iii) Epigenetic modifications

Epigenetic modification relevant to the characteristics

b) Functional assay

Response of the cells to a defined stimulus
 Behaviour of other biological entities after exposure to the cells
 If using accessory cells, describe phenotype and source

c) Cell numbers

i) Absolute cell number

Total number of cells at the end of the isolation process
 Methodology

ii) Viability

Percentage of viable cells
 Methodology

Must

Should

May

d) Dosing

Dose of cells transferred into organism (if applicable)

Vehicle (solvent/medium) and intermediate components
(for clinical trials only)

e) Quality control (for clinical trial only)

Specificity

Purity

Sterility

Potency

4. About the protocol

a) Regulatory authority

External authority that approved the protocol

Does protocol follow GMP?

b) Purpose

The disorder for which the cell treatment has been manufactured

c) Relationship between the source organism for the cells and the target organism

Allogeneic/Autologous/ Xenogeneic/Syngeneic

d) Contact details

Name and contact information of the corresponding author(s)

e) Citation

Acknowledge the MITREG reporting guidelines